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Abstract 
Drug resistance mutations are frequently detected in antiretroviral-naive HIV positive patients, however the data on 
transmitted resistance in non-B subtypes are limited. As HIV1 subtype F is prevalent in Romania, our goal is to analyze resistance 
mutations in the pol gene of HIV-1 isolates from drug-naive Romanian patients. HIV-1 pol gene from 12 untreated patients, newly 
diagnosed (n = 6) and chronically infected (n=6), with detectable HIV RNA viral load was genotyped and the viral subtype was 
determined by using the Stanford database algorithm. 8/12 strains belonged to the F subtype, 1/12 to the G subtype, and the rest of 
the studied strains appeared to be K/F, A/F and J/F inter-subtype recombinant forms. The prevalence of HIV-1 strains with at least 
one major drug resistance mutation in the studied group was unexpectedly high. Major mutations associated with NRTI, NNRTI and 
PI resistance were detected in 6/12 patients, 2/12 patients and 3/12 patients, respectively; in addition all viral strains had minor 
mutations in the protease gene. Newly diagnosed patients harbored resistant variants more often than chronically infected ones (4/6 
vs. 2/6) did. These data support the use of genotypic resistance testing in treatment-naive HIV positive patients, in order to guide the 
selection of the first line of antiretrovirals, due to the fact that persons with transmitted drug resistance have a higher risk for both 
virologic failure and development of resistance at treatment initiation.  
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Abbreviations: 
HIV - Human immunodeficiency virus; TDR  - transmitted drug resistance; HAART - highly active antiretroviral therapy ; 
SDRM - surveillance list of drug resistance mutations ; NRTIs - nucleos(t)idic reverse-transcriptase inhibitors; NNRTIs - 
non-nucleosidic reverse transcriptase inhibitors; PIs - protease inhibitors; TAMs - thymidine analogue mutations; 3TC - 
lamivudine ; FTC - emtricitabine ; ddI - didanosine ; ABC - abacavir ; ZDV - zidovudine ; d4T - stavudine ; TDF - tenofovir  
Introduction 
The transmission of drug-resistant HIV-1 has 
important implications for the successful management of 
antiretroviral therapy among  infected individuals, 
restricting drug options and increasing  the risk of 
suboptimal treatment outcomes. Persons with transmitted 
drug resistance (TDR) begin antiretroviral therapy with a 
lower genetic barrier to resistance, a higher risk of 
virologic failure, and a higher risk of developing resistance 
even to those drugs in their regimen that were originally 
fully active [1-3]. For these reasons, the new guidelines 
recommend to perform the genotypic resistance testing in 
all drug naive patients, before beginning a first line 
antiretroviral regimen [4].  
To date, there is a growing literature about the 
rate of transmission of HIV-1 drug-resistant viruses. In the 
United States and in Europe, where there is a wide 
access to highly active antiretroviral therapy (HAART), the 
prevalence of HIV-1 drug-resistant strains ranges 
between 3.3% and 14.0% in recently infected patients and 
between 6.1% and 12.5% in chronically infected ones [5-
10]. To accurately compare transmitted drug resistance 
rates across geographic regions and times, the World 
Health Organization has recommended the adoption of a 
consensus genotypic definition of transmitted HIV-1 drug 
resistance. Currently, a surveillance list of drug resistance 
mutations (SDRM) is constantly updated. The last 
updated SDRM list from 2009 has 93 mutations including Journal of Medicine and Life Vol. 4, No. 2, April‐June 2011 
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34 NRTI-resistance mutations at 15 RT positions, 19 
NNRTI-resistance mutations at 10 RT positions, and 40 
PI-resistance mutations at 18 protease positions [11]. 
The detection of transmitted HIV-1 drug 
resistance is dependent on various factors. In the 
absence of therapy, resistance mutations may decline 
over time and become undetectable by current assays, 
but may persist archived and cause treatment failure 
when ART is started. The identification of TDR is further 
complicated by the diversity of HIV across different types 
(HIV-1 and HIV -2), groups (main [M], outlier [O] and new 
[N]), subtypes and recombinant forms [12, 13-16] that are 
prevalent worldwide [17]. Group M accounts for over 99% 
of globally reported HIV/AIDS infections, and, is further 
classified into nine pure subtypes (A, B, C, D, F, G, H, J 
and K) and many circulating and other recombinant forms. 
HIV-1 nonsubtype B variants account for the majority of 
HIV infections worldwide, but are the least studied; most 
existing knowledge of HIV-1 pathogenesis and 
responsiveness to antiretroviral therapy is based on work 
carried out with subtype B viruses (most common in North 
America, Europe, and Australia).  
Previous studies showed that subtype F largely 
dominates the epidemiology of HIV-1 infection in Romania 
[18], where a major pediatric HIV epidemic with several 
thousand cases infected mainly through blood 
transfusions and injections with improperly sterilized 
equipment was reported at the end of ‘80s. According to 
the National Report of the HIV/AIDS Monitoring and 
Evaluation Department in Romania 
(http://data.unaids.org), at the end of 2009, a cumulative 
total of 16,162 cases of HIV and AIDS infection had been 
recorded, with 10,041 persons living with HIV/AIDS. The 
largest age group of people living with HIV/AIDS consists 
of young people (17-21 years) over 6,000, which are in 
fact long time survivors, infected between 1987 and 1992. 
The incidence of HIV/AIDS newly diagnosed cases 
decreased in Romania starting from 2004. The number of 
newly diagnosed patients in 2008 and 2009 was of 436 
and 428, respectively. Almost 50% of the newly cases of 
HIV/AIDS discovered in 2009 were among young persons 
aged 15 to 29.  
Considering the fact that data on non-B subtypes 
is limited, and subtype F is prevalent in Romania, our goal 
is to analyze resistance mutations in the pol gene of HIV-
1 isolates from antiretroviral-naive Romanian patients.  
Patients and methods 
This is a pilot study of 12 antiretroviral therapy 
naives HIV-1 infected patients, with clinically followed-up 
in “Dr. Victor Babes” Hospital in Bucharest. All patients 
had detectable HIV viral load, as determined by plasma 
HIV-1 RNA quantification (COBAS AMPLICOR HIV-1 
MONITOR TEST version 1.5; lower detection limit, 400 
copies/ mL ARN HIV-1; linear range between 400 
(log10=2.6) to 750,000 (log10=5.87) copies/mL ARN HIV-
1). Drug resistance genotyping was performed using the 
TruGene HIV-1 Genotyping Assay (SIEMENS). This 
technique consists of an RT reaction performed on HIV 
RNA extracted from plasma, followed by PCR 
amplification of a 1,318-bp fragment of the pol gene and 
CLIP sequencing of the PCR amplicons using HIV-1 
specific primers. Separation of the CLIP sequencing 
reactions by electrophoresis on a polyacrylamide gel, and 
detection by laser- induced fluorescence is followed by 
analysis using the OpenGene DNA System Software, with 
a HIV-1 Resistance Report issued for each sample. For 
subtyping purposes and drug resistance interpretation, all 
sequences were submitted to the Stanford University HIV 
database. Mutations associated with transmitted drug 
resistance (TDR) were identified using the WHO 2009 list 
of mutations for surveillance of TDR HIV strains 
http://hivdb.stanford.edu/pages/WHOResistanceList.html. 
Results 
Study population. All 12 study patients were 
naive for therapy at the time of HIV resistance testing: 6 
were newly diagnosed cases of HIV infection, and 6 were 
known to be chronically infected (for more than 1 year). 
There were 6 males and 6 females, with a median age of 
30,5 years (range from 7 to 39 years). In the group of 
newly diagnosed patients (mean age 33.8 years) the 
transmission route was heterosexual contact, while 
chronically infected patients (mean age of 21 years) were 
long-term survivors, with HIV parenterally acquired during 
childhood. There were no significant differences in the 
median CD4+ cell count in the two subgroups of patients 
(232 cell/mm³ for newly diagnosed patients vs 303 
cell/mm³ for chronically infected ones). The median HIV 
RNA viral load was higher in newly diagnosed individuals 
(235 400 HIV RNA copies/mL) than in persons with 
chronic infection (126 650 HIV RNA copies/mL). HIV-1 
subtype analysis indicated that 8 out of the 12 strains 
belonged to the F subtype, one to the G subtype, while 
the rest appeared to be K/F; A/F or J/F inter-subtype 
recombinant forms. 
 
Prevalence of drug resistance mutations. Among the 
12 drug-naïve patients included in the study, 6 carried HIV 
strains with at least one resistance-related mutation 
(Figure 1). 
Newly diagnosed patients harbored resistant 
variants more often than the chronically infected ones 
(4/6; 66.6% vs. 2/6; 33.3%) did. Resistance to 2 drug 
classes was present in 2/12 (16.6%) patients, and 
resistance to all three drug classes was observed in other 
2 cases.  
Mutations associated with resistance to 
nucleoside reverse transcriptase inhibitors (NRTIs) were 
detected most frequently (in 6 out of 12 patients), followed 
by non-nucleoside reverse transcriptase inhibitor (NNRTI) 
resistance mutations (in 3 out of 12 patients) and 
protease inhibitor (PI) resistance mutations (in 3 out of 12 
patients).  Journal of Medicine and Life Vol. 4, No. 2, April‐June 2011 
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Major mutations associated with NRTI resistance 
were observed in 6 out of the 12 studied patients. 
Mutations known to be selected by thymidine analogues, 
termed TAMs were the most predominant (5/12; 41,6%), 
TAMs 2 being more frequently detected (3/12; 25%): 
K70R and K219Q (each in 2 cases), D67N and T215F 
(each in one case) - all associated with resistance to AZT, 
d4T, 3TC. The only TAM1 observed was M41L, found in 2 
cases. In vitro, this mutation causes high-level resistance 
to lamivudine (3TC) and emtricitabine (FTC), low-level 
resistance to didanosine (ddI) and abacavir, (ABC) and 
increased susceptibility to zidovudine (ZDV), stavudine 
(d4T), and tenofovir (TDF). The revertant mutation at 
codon 215 (T215N), associated with an increased risk of 
virologic failure was identified in one drug-naïve 
individual. M184V, the 3TC- selected mutation, was found 
in only one patient together with all the above mentioned 
TAMs.   
Major mutations K103N and Y181C associated 
with primary NNRTI resistance were observed each in 
one of the newly diagnosed patients. 
Regarding PI resistance, major mutations were 
observed in 3 out of the 12  drug-naïve patients with 
V82A/S/T present in all cases, either alone or 
accompanied by I84L in one case and M45I, I47V, I54V in 
the other one.  
All the studied HIV-1 strains had minor mutations 
in the protease gene. M36I, was the most common 
accessory protease inhibitor resistance mutation, found in 
all studied patients, and followed by E35D (in 10 cases), 
K20R and I15V (in 9 cases). M36I is one of the 
polymorphic substitutions in subtype F and other non-B 
HIV proteases that may lead to early development of drug 
resistance in patients infected with non-B subtypes. The 
L89M polymorphism, the most prevalent signature among 
treatment-naive non–subtype B isolates, was found in 
9/12 patients. Mutations L63T (present in 7 cases) and 
L10V (present in 3 cases) have been suggested as 
predictors of virological failure in patients who had been 
treated with multiple antiretroviral drugs. 
Discussion  
We have found a strikingly high HIV-1 TDR 
mutation rate in our small group of patients. Half of the 
studied patients were harboring primary HIV-1 drug 
resistance mutations, mainly associated with NRTI 
resistance. This is the first report on the presence of 
major mutations in treatment-naive HIV-positive 
Romanian patients. A previous study conducted in ”Matei 
Bals” Institute of Infectious Diseases on a sample of 29 
drug-naive HIV-positive patients revealed no major 
mutations associated with resistance to NRTIs, NNRTIs, 
and PIs [19].   
The baseline resistance was more common in 
newly diagnosed individuals than in chronically infected 
patients (66.6% vs 33.3%). The lower prevalence of 
resistance in chronic infection is most likely due to a lower 
exposure to drug-resistant virus in the past. In addition, 
the lower prevalence can be explained by reversion from 
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Fig.1 Prevalence of primary resistance. Half of the studied patients were harboring primary HIV-1 drug resistance mutations, 
mainly associated with NRTI resistance. Newly diagnosed patients carried resistant variants more often than did chronically 
infected ones (4/6; 66.6% vs. 2/6; 33.3%). Resistance to 2 drug classes was present in 2/12 (16.6%) patients, and resistance to 
all three drug classes was observed in other 2 cases.  Journal of Medicine and Life Vol. 4, No. 2, April‐June 2011 
  154  © 2011, Carol Davila University Foundation
resistant variants to sensitive wild-type viruses over time 
[20]. Interestingly, drug-resistance mutations could still be 
detected in the plasma of quite a few chronically infected 
patients, which indicates that complete reversion does not 
always occur. Indeed, many studies have indicated that 
drug-resistant viruses can persist for a couple of years in 
the plasma of treatment-naive HIV-infected patients [21, 
22].   
The persons who have been infected for more 
than 1 year are considered to be chronically infected. The 
duration of HIV infection in newly diagnosed individuals is 
usually unknown and can be highly variable. To 
differentiate recent from chronic HIV-1 infections among 
newly diagnosed patients it is necessary to perform the 
BED IgG-Capture enzyme immunoassay (BED-CEIA). 
The recent infection is confirmed by this method, which is 
based on the principle that characteristics of the initial HIV 
antibody response in recent infections differs from those 
of established or long-term infections either by antibody 
titer, proportion, specificity, isotype or avidity. 
We also found that half of our subjects harbour 
HIV-1 strains with at least one major drug resistance 
mutation.  
The most frequent substitutions of amino acids in 
reverstranscriptase gene belong to the TAM category, a 
fact that may compromise the efficacy of most drugs from 
this class. It is interesting to note that although both TAM-
1 and TAM-2 pathway mutations were encountered, the 
TAM-2 pathway was the better represented, in contrast 
with the available data obtained from subtype B strains 
[23]. Type I TAM cause higher levels of phenotypic and 
clinical resistance to the thymidine analogs and cross-
resistance to abacavir, (ABC), didanosine (ddI), and 
tenofovir (TDF), than do the type II TAMs [24]. 
Mutation M184V was found in only one HIV-1 
strain, subtype F, together with D67N, T69D, K70R, L74I, 
T215F and K219Q. As this mutation tends to be rapidly 
archived, its presence together with the other mentioned 
TDR suggests a recent infection with a resistant HIV-1 
strain. The phenotypic and clinical significance of M184V 
is influenced by the presence or absence of other NRTI 
resistance mutations. Four TAMs in combination with 
M184V cause high-level resistance to both ABC and ddI 
[25 -29]. The presence of the T215 revertant suggests a 
previous infection with a HIV-1 strains containing T215Y/F 
[30, 31], and has been associated with an increased risk 
of virologic failure in patients receiving a first line regimen 
with thymidine analogue [32]. Mutations K103N and 
Y181C, presented in 2 newly diagnosed patients, confer 
cross-resistance to all NNRTIs. Major mutations 
associated with PI resistance were observed at positions 
46, 47, 54, 82 and 84, conferring resistance to the most 
important PIs used in antiretroviral treatment. 
All the studied HIV-1 strains carried many minor 
mutations with high frequencies in the protease gene. 
These mutations are often found at polymorphic positions 
and may have limited effect on susceptibility to 
antiretroviral drugs. However, these mutations should be 
considered when assessing the possible impact on the 
therapy response as they have been reported to be 
associated with high viral fitness in strains with major 
mutations [33,34,35,39]. One consequence of preexisting 
accessory mutations might be the faster emergence of 
viruses resistant to PIs.  
We observed the presence of TDR in 2 patients 
who had risk factors in acquiring the infection in early 
childhood, and therefore we considered them to be 
parenterally-infected. As an infection with a TDR viral 
strain at the beginning of HIV epidemic is doubtful, we 
may take into consideration the possibility of a 
superinfection with a resistant HIV-1 recently acquired, 
probably by a sexual route.  
This high rate of TDR in patients infected with F 
subtype is conflicting with previous European reports 
regarding TDR, where non-B subtypes were harboring 
less TDR mutations [40, 41]. The explanation can be 
related to the fact that HIV epidemic in Romania has been 
evolving over 2 decades and many patients have been 
exposed to antiretroviral therapy. Some of them, failing 
ARV regimens, are prone to transmit HIV-1 strains with 
TDR mutations. Also the group of children infected in the 
early 1990 became sexually active and from an 
epidemiological point of view represent a group with high 
risk to transmit HIV-resistant strains [42].  
Regarding the subtype distribution in our study, 
even if F subtype remains prevalent, we observed an 
increase of HIV-1 infections which involved other 
subtypes and inter-subtype recombinant forms, aspect 
that has to be further confirmed by detailed genotyping 
studies. We could not find a difference between the rates 
of TDR in patients infected with F strain, compared to 
those infected with other strains.  
From the point of view of TDR subtype, diversity 
raises some questions because of polymorphism 
mutations (drug resistance mutations that occur 
commonly in the absence of drug selective pressure). For 
C clade, baseline polymorphism at codon 106 has 
facilitated the development of a novel V106M mutation, 
conferring efavirenz resistance [43]. Protease inhibitor 
mutations L89I/V have been reported in C, F and G 
subtypes [44]. A review on non-B subtype performed by 
Cajas and collaborators showed that polymorphisms that 
were common in non-B subtypes and that may contribute 
to resistance, tended to persist or become more frequent 
after drug exposure. The authors outlined that some, but 
not all are recognized as minor resistance mutations in B 
subtypes, and that these observed differences in 
resistance pathways may impact cross-resistance and the 
selection of second-line regimens with protease inhibitors. 
Attention to newer drug combinations, as well as baseline 
genotyping of non-B isolates, in well-designed longitudinal 
studies with long duration of follow up are needed. 
The limitation of our study is related to the small 
study group. Further studies are needed in order to 
evaluate if this high rate reflect the present situation in Journal of Medicine and Life Vol. 4, No. 2, April‐June 2011 
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Romania, where many patients have been exposed to 
antiretroviral treatment for over a decade, and if they are 
failing their current regimens and might transmit HIV-
antiretroviral resistant strains.   
Conclusion  
The prevalence of HIV-1 strains with at least one 
major drug resistance mutation in the studied group was 
very high, major mutations being more frequently 
identified among newly diagnosed patients compared to 
chronically infected patients. These data supports the use 
of genotypic resistance testing in treatment-naive HIV 
positive patients, especially in newly diagnosed ones, in 
order to guide the selection of the first line of antiretroviral 
treatment. 
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